Biotech startup StrainX Bioworks raises $13 million from Prime Venture, Leo Capital, others

StrainX Bioworks, a biotech startup specializing in synthetic biology and precision fermentation, has secured $13 million in funding. The round was led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT Angels. Founded by IIT Delhi alumni Akshay Mittal and Alok Malaviya, the company has operated in stealth mode for two years, expanding its team to over 100 members, including 15 PhDs. StrainX has developed an integrated biotechnology platform covering strain engineering, fermentation, process scale-up, and product development. Precision fermentation uses genetically modified microbes like yeast or bacteria to produce proteins, enzymes, and other compounds. Mittal explained that synthetic biology involves engineering microbes through genetic coding to manufacture high-value products using fermentation systems. The startup has already demonstrated fermentation at a 10,000-litre scale and is preparing to scale up to 100,000-litre capacity for commercial production. StrainX targets high-value food and beverage ingredients, such as those used in chocolates, icing, and nutritional applications, alongside alternative proteins and pharmaceutical products. The company is engaging with global food and beverage companies and large distribution players for supply partnerships, with discussions ongoing with 20-30 firms worldwide. Mittal noted that few companies globally can combine molecular biology, strain engineering, and large-scale fermentation at commercially viable prices. He also highlighted India’s potential to become a leader in biological systems and next-generation manufacturing. The new funding will support research and development, team expansion, and accelerating commercialization through global partnerships and large-scale fermentation projects.